ANI Pharmaceuticals Acquires New Drug Applications from Sandoz.

MANews-(C)2009-2021

US-based ANI Pharmaceuticals, Inc (NASDAQ: ANIP) has acquired the new drug applications for Oxistat Lotion, Veregen Ointment, and Pandel Cream and the abbreviated new drug application for ApexiCon E Cream from German drugmaker Sandoz Inc, the company said.

Pandel Cream will be transitioned later upon receiving the requisite approvals. Collectively, these products generated net revenues of USD 13.2m in 2020.

The acquisition was funded through borrowings under the company's pre-existing revolver credit facility.

In conjunction with the acquisition, ANI and Sandoz have entered into a multi-year manufacturing and supply agreement for Oxistat Lotion, Pandel Cream and ApexiCon E Cream.

ANI said I tplans to transfer the manufacture and packaging of these three products to its own manufacturing sites in the future.

Oxistat Lotion is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum.

Pandel is...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT